10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Blimp-1–dependent and –independent natural antibody production by B-1 and B-1–derived plasma cells

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The transcriptional regulator of B cell differentiation, Blimp-1, regulates antibody production by plasma cells after antigen stimulation. Savage et al. demonstrate that spontaneous “natural” IgM and IgG3 production is provided by a heterogeneous set of B-1–derived plasma cells and by B-1 cells; the latter neither express nor require Blimp-1 for maximal antibody production.

          Abstract

          Natural antibodies contribute to tissue homeostasis and protect against infections. They are secreted constitutively without external antigenic stimulation. The differentiation state and regulatory pathways that enable continuous natural antibody production by B-1 cells, the main cellular source in mice, remain incompletely understood. Here we demonstrate that natural IgM-secreting B-1 cells in the spleen and bone marrow are heterogeneous, consisting of (a) terminally differentiated B-1–derived plasma cells expressing the transcriptional regulator of differentiation, Blimp-1, (b) Blimp-1 +, and (c) Blimp-1 neg phenotypic B-1 cells. Blimp-1 neg IgM-secreting B-1 cells are not simply intermediates of cellular differentiation. Instead, they secrete similar amounts of IgM in wild-type and Blimp-1–deficient (PRDM-1 ΔEx1A) mice. Blimp-1 neg B-1 cells are also a major source of IgG3. Consequently, deletion of Blimp-1 changes neither serum IgG3 levels nor the amount of IgG3 secreted per cell. Thus, the pool of natural antibody-secreting B-1 cells is heterogeneous and contains a distinct subset of cells that do not use Blimp-1 for initiation or maximal antibody secretion.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: not found

          B cell development pathways.

          B cell development is a highly regulated process whereby functional peripheral subsets are produced from hematopoietic stem cells, in the fetal liver before birth and in the bone marrow afterward. Here we review progress in understanding some aspects of this process in the mouse bone marrow, focusing on delineation of the earliest stages of commitment, on pre-B cell receptor selection, and B cell tolerance during the immature-to-mature B cell transition. Then we note some of the distinctions in hematopoiesis and pre-B selection between fetal liver and adult bone marrow, drawing a connection from fetal development to B-1/CD5(+) B cells. Finally, focusing on CD5(+) cells, we consider the forces that influence the generation and maintenance of this distinctive peripheral B cell population, enriched for natural autoreactive specificities that are encoded by particular germline V(H)-V(L) combinations.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells.

            Blimp-1 is a transcriptional repressor able to drive the terminal differentiation of B cells into Ig-secreting plasma cells. We have created mice with a B cell-specific deletion of prdm1, the gene encoding Blimp-1. B cell development and the number of B cells responding to antigen appear to be normal in these mice. However, in response to either TD or TI antigen, serum Ig, short-lived plasma cells, post-GC plasma cells, and plasma cells in a memory response are virtually absent, demonstrating that Blimp-1 is required for plasmacytic differentiation and Ig secretion. In the absence of Blimp-1, CD79b(+)B220(-) pre-plasma memory B cell development is also defective, providing evidence that this subset is an intermediate in plasma cell development. B cells lacking Blimp-1 cannot secrete Ig or induce muS mRNA when stimulated ex vivo. Furthermore, although prdm1-/- B cells fail to induce XBP-1, XBP-1 cannot rescue plasmacytic differentiation without Blimp-1.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              B-1 and B-2 Cell–Derived Immunoglobulin M Antibodies Are Nonredundant Components of the Protective Response to Influenza Virus Infection

              We have studied the role of secreted immunoglobulin (Ig)M in protection from infection with influenza virus and delineated the relative contributions of B-1 versus B-2 cell–derived IgM in this process. Mice deficient in secreted IgM but capable of expressing surface IgM and secreting other Ig classes show significantly reduced virus clearance and survival rates compared with wild-type controls. Irradiation chimeras in which only either B-1 or B-2 cells lack the ability to secrete IgM show mortality rates similar to those of mice in which neither B-1 nor B-2 cells secrete IgM. Dependence on both sources of IgM for survival is partially explained by findings in allotype chimeras that broadly cross-reactive B-1 cell–derived natural IgM is present before infection, whereas virus strain–specific, B-2 cell–derived IgM appears only after infection. Furthermore, lack of IgM secreted from one or both sources significantly impairs the antiviral IgG response. Reconstitution of chimeras lacking B-1 cell–derived IgM only with IgM-containing serum from noninfected mice improved both survival rates and serum levels of virus-specific IgG. Thus, virus-induced IgM must be secreted in the presence of natural IgM for efficient induction of specific IgG and for immune protection, identifying B-1 and B-2 cell–derived IgM antibodies as nonredundant components of the antiviral response.
                Bookmark

                Author and article information

                Journal
                J Exp Med
                J. Exp. Med
                jem
                jem
                The Journal of Experimental Medicine
                The Rockefeller University Press
                0022-1007
                1540-9538
                04 September 2017
                : 214
                : 9
                : 2777-2794
                Affiliations
                [1 ]Graduate Group in Immunology, University of California, Davis, Davis, CA
                [2 ]Center for Comparative Medicine, University of California, Davis, Davis, CA
                [3 ]Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, CA
                [4 ]Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL
                Author notes
                Correspondence to Nicole Baumgarth: nbaumgarth@ 123456ucdavis.edu

                V.M. Yenson’s present address is Quintiles, Chatswood, Australia.

                Author information
                http://orcid.org/0000-0002-1057-7239
                http://orcid.org/0000-0002-2891-4483
                Article
                20161122
                10.1084/jem.20161122
                5584113
                28698287
                56926bcd-7d02-4d0c-8c0e-4e71868e1eb3
                © 2017 Savage et al.

                This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

                History
                : 18 July 2016
                : 27 April 2017
                : 08 June 2017
                Funding
                Funded by: National Institutes of Health, DOI http://dx.doi.org/10.13039/100000002;
                Award ID: NIH/NIAID R01AI051354
                Award ID: R01AI085568
                Award ID: U19AI109962
                Funded by: National Center for Advancing Translational Sciences, DOI http://dx.doi.org/10.13039/100006108;
                Award ID: UL1 TR000002
                Award ID: TL1 TR000133
                Award ID: 2T32OD010931-09
                Award ID: 5T35OD010956-14
                Award ID: T-32 AI060555
                Categories
                Research Articles
                Article

                Medicine
                Medicine

                Comments

                Comment on this article